Search the Newsreel

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is actively developing several weight management drugs and recently acquired Metsera, significantly boosting its pipeline in this growing market. While Pfizer has promising candidates, particularly MET-097i with potential for monthly dosing, it faces strong competition from market leaders like Eli Lilly and Novo …

Lobbying Update: $60,000 of PFIZER lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that Pfizer (PFE) disclosed $60,000 in lobbying expenditures for Q2 2026. The lobbying efforts focused on issues including drug development and pricing, vaccine safety and access, the 340B program, and pharmacy benefit managers. The article also provides …

Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged

Pfizer (NYSE:PFE) shares rose 3.6% last week, outperforming the S&P 500, primarily due to the appeal of its 6.9% dividend yield rather than an increase in earnings forecasts. Analyst expectations for 2026 earnings actually saw a slight decrease. The company also saw a new …

Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention

The article argues that the Enanta v. Pfizer case is not merely about a typographical error in a patent application, but rather about whether the inventors possessed the invention prior to Pfizer's public disclosure of nirmatrelvir. It claims the Federal Circuit applied the wrong …

The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges including cold chain requirements, and its safety profile based …

Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research

This article identifies three AI healthcare stocks—Pfizer (PFE), Tempus AI (TEM), and Medtronic (MDT)—as compelling for further research, given the growing importance of AI in diagnostics, treatment, and efficiency within the healthcare sector. It highlights their individual strengths, such as Pfizer's broad portfolio and …

Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer

Pfizer (PFE) recently received FDA approval for PADCEV plus Keytruda for muscle-invasive bladder cancer, which could suggest a 16% undervaluation based on a fair value of $29.19 per share. Despite past share price pressure, the new oncology approval and strong late-stage pipeline in oncology …

ETFs Investing in Pfizer Inc. Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold Pfizer Inc. (PFE) stocks. It provides a detailed table including each ETF's market value, weight of PFE in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV …

EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer has temporarily suspended sales of Premarin vaginal cream in India due to supply challenges, significantly impacting the estrogen therapy options for millions of women experiencing menopause-related symptoms in the country. This suspension affects over half of the market for this type of medication …

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

Pfizer's stock is trading below its 50-day and 200-day simple moving averages, indicating investor caution due to declining COVID-related revenues and upcoming patent expirations. Despite these challenges and a dull 2026 financial outlook, the company is rebuilding its pipeline in oncology and obesity through …

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement …

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV’s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer’s near-term cancer pipeline, the article notes that it doesn't fully mitigate the larger concerns of …

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna Inc. and Pfizer Inc., seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that these vaccines infringe upon as many as 10 of its mRNA delivery patents. The lawsuits were filed in the US District …

Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC

Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This approval expands on a previous FDA …

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point

Is Pantera Minerals Ltd (ASX: PFE) Positioning for the Next Battery Minerals Cycle?

Pfizer Inc. (PFE) Stock: FDA Clears IBRANCE for HER2+ Breast Cancer

Pfizer-Aktie fällt nach Bestätigung der Prognose für das Geschäftsjahr 2026

Pfizer (PFE) Stock: Pfizer’s $26 Share Price and 6.6% Dividend Yield Face Drug Pricing and Patent Pressure

Pantera Minerals (ASX:PFE) Advances U.S. Critical Minerals Project Ahead of Drilling

Pfizer Stock at $25: A $29 Wall Street Mean Target Backed by Two Legal Wins and 22% Portfolio Growth

Dividend Healthcare Giants: Analyzing Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) for 2026

Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT): Three Dividend Healthcare Stocks to Consider in 2026

Is Pfizer Stock Worth Buying After a Q1 2026 Beat and Patent Win?

Pfizer Stock Gains Ground Following Better Than Expected Q1 Financial Results

Dividenden-Aktie Pfizer: Erwartungen übertroffen – Prognose steht

Pfizer stock price forecast: sideways trading expected as PFE consolidates above key supports

Pfizer Aktie Prognose: Kursziele von Drittanbietern

Pfizer (PFE) Stock: COVID-19 Revenue Decline Spurs Strategic Shift

Pfizer Aktie unter Druck nach vorsichtiger Prognose – lohnt es sich jetzt, Aktien zu kaufen? 💊

Neue Prognose vorgestellt: Pfizer-Aktie: KGV 8,8 und 6,7 % Dividende - jetzt zuschlagen?

Pfizer (PFE) Stock: Analyst Price Targets Reflect Cautious Market Sentiment

Pfizer Aktie Prognose 2025: Mega-Chance für Aktionäre oder tickende Zeitbombe?

Pantera Minerals Ltd (ASX:PFE)